Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

par Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D’Incà, Edoardo Vincenzo Savarino
Publié 2021

Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease.

par Anna Latiano, Orazio Palmieri, Luca Pastorelli, Maurizio Vecchi, Theresa T Pizarro, Fabrizio Bossa, Giuseppe Merla, Bartolomeo Augello, Tiziana Latiano, Giuseppe Corritore, Alessia Settesoldi, Maria Rosa Valvano, Renata D'Incà, Laura Stronati, Vito Annese, Angelo Andriulli
Publié 2013